2-Aminoindane (2-AI) is an aminoindane and research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. It acts as a selective substrate for NET and DAT.

Therapeutic and illicit uses

Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters. 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat discrimination tests.

Chemical derivatives

There are a number of notable derivatives of 2-aminoindane that exist, including: • 5-IAI • Aprindine • BFAI • DHAI • ETAI • Indanorex • Indantadol • MDAI • MEAI (5-MeO-AI) • MDMAI • MMAI • NM-2-AI • PNU-99,194 • TAI A number of notable derivatives of 1-aminoindan, a positional isomer of 2-aminoindan, also exist, such as rasagiline and ladostigil, among others. Jimscaline, 2CB-Ind, and AMMI are derivatives of 1-aminomethylindane, an indane- and amine-containing compound related to 1-aminoindan.

Pharmacology

Legal status

China

As of October 2015 2-AI is a controlled substance in China.

Sweden

Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.

United States

2-Aminoindane is not scheduled at the federal level in the United States, but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.